Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Inclusion Criteria

• •Histologically confirmed newly diagnosed Stage III/IV epithelial ovarian or primary peritoneal carcinoma at time of initial diagnosis
• •Treatment must start within 8 weeks of surgery
• •Subjects may be measurable per RECIST criteria or evaluable for disease response by CA125. Evaluable CA 125 levels are defined as an elevated CA125 pre operatively which either remains elevated post-operatively or normalizes after surgery
• •No prior chemotherapy or radiation therapy
• •Age ≥ 18
• •Performance Status must be ≤ 2 (ECOG)
• •Peripheral neuropathy: must be ≤ grade 1
• •Hematologic (minimal values)
• •* Absolute neutrophil count ≥ 1,500/mm3
• •* Hemoglobin ≥ 8.0 g/dl
• •* Platelet count ≥ 100,000/mm3
• •Hepatic
• •\*Total Bilirubin ≤ ULN
• •AST and ALT and Alkaline Phosphatase must be within the range allowing for eligibility.